Golgi Protein for HCC Diagnosis

Screening for Hepatocellular Carcinoma Clinical Trial

Official title:

Golgi Protein 73 for Diagnosis of HCC in Egyptian Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03039322
• Other study ID #: 914
• Status: Completed
• Phase: N/A
• First received: January 31, 2017
• Last updated: January 31, 2017
• Start date: December 22, 2014
• Est. completion date: December 30, 2015

Study information

• Verified date: January 2017
• Source: Ain Shams University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This case-control study was conducted on 90 patients who were equally divided into two groups. Group 1 included 45 patients with HCV-related chronic liver disease without clinical or radiological evidence of HCC (control group), and Group 2 included 45 patients diagnosed to have HCC by Triphasic abdominal CT (patient group). Serum AFP and GP73 were measured using ELISA technique

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: December 30, 2015
• Est. primary completion date: December 30, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• patients were older than 18 years.

Exclusion Criteria:

• patients with hepatic focal lesions not due to HCC such as Hemangioma, Hepatic cyst, and liver metastases; patients infected with HIV; patients with any autoimmune disease; or patients with metastatic disease.

Related Conditions & MeSH terms

• Carcinoma, Hepatocellular
• Screening for Hepatocellular Carcinoma

Intervention

Diagnostic Test:
• Serum Golgi Protein 73
Serum test

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Ain Shams University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Golgi protein correlated with presence of HCC		within one year